Clinical Trials Browser

Colonic Neoplasms, Glioblastoma, Lung Neoplasms, Neoplasms, Pancreatic Neoplasms, Disease Progression

NCT03586661 2026-03-11

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 1 Active not recruiting

31 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Disease Progression

NCT07137871 2025-10-31

Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy

Phase 1 Recruiting

35 enrolled

Disease Progression

NCT02766699 2025-06-03

CerebralEDV

Phase 1 Completed

9 enrolled

CNS

Brain Neoplasms, Glioblastoma, Neoplasms, Neoplasms by Site, Recurrence, Disease Progression

NCT01543763 2025-03-21

Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

Phase 1 Completed

90 enrolled

Sarcoma

Neoplasm Metastasis, Sarcoma, Disease Progression

NCT02043847 2024-11-13

BMT-03

Phase 1 Completed

12 enrolled 12 charts

Plasma cell

Multiple Myeloma, Recurrence, Disease Progression

NCT06622174 2024-10-02

PROMISE

Phase 1 Not yet recruiting

32 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Disease Progression

NCT03546426 2024-10-01

MESOVAX

Phase 1 Active not recruiting

18 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant, Disease Progression

NCT03422393 2024-07-05

Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib

Phase 1 Active not recruiting

24 enrolled

LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Disease Progression

NCT02135406 2023-06-22

CART-19 for Multiple Myeloma

Phase 1 Completed

13 enrolled

Plasma cell

Multiple Myeloma, Disease Progression

NCT04005144 2022-10-17

Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

Phase 1 Terminated

3 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Disease Progression

NCT02189343 2019-11-21

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Phase 1 Completed

16 enrolled

Plasma cell

Disease, Multiple Myeloma, Recurrence, Disease Progression

NCT02586987 2019-11-18

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

Phase 1 Completed

58 enrolled

BreastDermatologicGastrointestinalThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms, Disease Progression

NCT01355965 2017-09-19

Autologous Redirected RNA Meso-CIR T Cells

Phase 1 Completed

18 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant, Disease Progression

NCT01692262 2014-06-19

PYRUS

Phase 1 Completed

59 enrolled

Genitourinary

Prostatic Neoplasms, Disease Progression

Clinical Trials

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy

CerebralEDV

Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

BMT-03

PROMISE

MESOVAX

Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib

CART-19 for Multiple Myeloma

Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

Autologous Redirected RNA Meso-CIR T Cells

PYRUS